Member Info for Diversified

When looking at the director holdings and other major shareholders, it is reasonable to assume that there is a very low free float of shares.

It won’t be long before this company gains traction with similar share price appreciation to ENSI. Accumulation is certainly taking place whilst this remains under the radar.

The last few trading days has not been without a block buyer. Today is further evidence of that and should be a good day.

Expecting uk launch imminently

Superdrug do appear to have an ED arm to their business. It may well just be very coincidental but the eroxon(r) brand certainly has found it’s place within google already which is highly encouraging.

I tried my wife’s phone and no sponsored link either. I find it strange as my Algos certainly wouldn’t have beauty products programmed into any targeted marketing campaign lol.

Will watch with interest.

I assume that when others google ‘eroxon(r)’ Superdrug comes up as a sponsored link?

Of significance given that eroxon(r) are yet to launch, and that both the SEO and the algorithms picks eroxon(r) as a key word for Superdrug.

In 2021 Superdrug had a turnover £1.2b.

Unlike other FDA approvals that had seen an initial rise only to fall back such as POLX and AGL, you can see a clear strategy to market with this behind the counter product. Revenue/commercialization will be quicker here with revenue from multiple regions. This is what excites me. No need for massive raises and slow and laborious routes to market.

Every reason to believe that this is going blue today following that interview and watching the trades. Liking what I hear.

Difference being, now they have the money in the bank to secure a rig.

Would dilution have been more or less without an MOU for a potential rig going into that raise?

What were the rig contractors asking for? Money they didn’t have?

It’s now an entirely different ball game.

Judging by what I have read today, a signed contract with scheduled mobilization would see a rise to 8/10p alone. That’s 45/90% return! Then when mobilization and subsequent spud is announce, add in a few on site tweets. 15/20p easily achievable (200/270% returns). Just need patientance and faith in what many have proclaimed to be a challenging environment for securing a rig (without listening to what they are actually saying).

Questions I have to ask myself:

- Annual administrative expensive $2.3m

Has the oversubscribed raise afforded the company additional time to secure a new rig?

With cash in place is the company in a better position to negotiate a new rig contract?

- Having read many posts from various people on here prior to this news, all of which were positive. In exchange for time would you have been happy to have participated in the raise at a marginal premium?

Sfibp - These boards have always been that way. It will never change.

In todays market one of the biggest risk factors is a companies ability to raise funds. With this now in place, and at only 6% above the oversubscribed raise, it would appear to be underpinning the current market cap. An entry at these levels for new entrants is compelling.

When it comes to a new rig, with funding in place the company is now better positioned to secure a rig. Let’s wait and see what the company comes up with as todays entry price more than compensates for any delay.

Many economists are expecting a global downturn in 2023 as economic conditions worsen in the face of tighter liquidity, in turn the availability of rigs should improve. But I expect them to secure a rig in a timely fashion regardless of market conditions.

Disgruntled sellers looking for a lower entry point that won’t come. They will kick around until their newly raised capital from todays sale is redeployed elsewhere and they lose interest in HE1.

Next update will come soon to satisfy market, and low and behold all will be forgotten. Seen this play out time and time again.

With the placing oversubscribed you can see that many are still taking opportunity of these lower prices.

Without the negative nellies this opportunity wouldn’t exist. Once they get bored I fully expect this to recover to 7p prior to an update on the next rig. Secured with cash in hand.

Going into rig discussions with funding in place makes it far easier to secure a rig.

An MOU was appropriate to secure funding, now funding is in place it doubles from here just on mobilization.

Todays project update has presented new and serious existing investors with a fantastic opportunity to purchase shares at or near to the placing price.

Fully funded and geologically spud ready, get us that rig and let the fun begin.

Can’t wait and thank you Invictious energy for this entry point.

I think those that don’t travel are missing the point.

1. Requirements are for a PCR test not lateral flow.

2. For the UK to renegade on most recent comms to the point that they now require testing is further confirmation that their is a bigger issue afoot (new variant of concern)

Valueinv. With all due respect, it’s that opinion that has led to an underwhelming valuation prior to this decision by comparison to the first fda cycle.

Not only that the two tech’s are at completely different stages within their respective developed industry cycles.

It is reasonable to suggest that with approx 50% of the market cap represented by cash leaving corporate core assets valued at just over £16m, with a turnover of a few million and decent news flow soon to kick in.

This is purely a case of poor liquidity through a lack of volume/interest. Let the news flow tell the story. It’s been a slow start and it’s now time for management to deliver on its admission document.

RUA submitted its (510k) today. Also reported revenue of less than a quarter of Genincode, and only has £4.7m as of March, compared to Genincode £17m cash pile.

With a market cap equal to Genincode’s and up 6.6% on the day, targeting a smaller market opportunity. Explain the market cap with £12/13m cash differential and tell me that Genincode is not significantly undervalued

Transfer of stock perhaps into sipp or between Isa’s

But definitely some nice buys at a great price today. Our time is coming.

Over the coming months, we will target the following key deliverables:

-- Develop Cardio inCode (R) launch program with Eversana for introduction to US market in 2022

-- Continue to progress our Breakthrough Device Designation discussions with FDA for Cardio inCode (R)

-- File Cardio inCode (R) de-novo submission for US regulatory approval with the FDA

-- Establish CPT coding for Cardio inCode (R) and commence CMS payer and reimbursement discussions

-- Complete RB&H set-up and commissioning for Lipid inCode (R) hypercholesterolemia testing

-- Complete Indiana University and New York Presbyterian collaborations as flagship facilities for introduction of Cardio inCode (R) and Thrombo inCode (R)

-- Appoint US CLIA (Clinical Laboratory Improvement Amendments) authorized testing facility

-- Complete and publish NHS Hypercholesterolemia study for Lipid inCode (R)

-- Advance RB&H Lipid inCode hypercholesterolemia product with NHS, AHSN's and Private payer networks

-- Complete our first COVID-19 Thrombo inCode (R) evaluation study for genetic predisposition to thrombosis

This is why I am happy to be of the journey. It’s a transformational period, and I have skipped all the initial trials that cost money and time. Roll on commercialization.